Milwaukee, WINCT06680037Now EnrollingIRB Ready

B-cell Mediated Autoimmune Disorders Clinical Trial in Milwaukee, WI

Access cutting-edge b-cell mediated autoimmune disorders treatment through this clinical trial at a research site in Milwaukee. Study-provided care at no cost to qualified participants.

Sponsored by TG Therapeutics, Inc.

Quick Self-Assessment

See if you qualify for this Milwaukee location

Preparing your pre-screening questions…

Expert Care in Milwaukee

Access b-cell mediated autoimmune disorders specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related b-cell mediated autoimmune disorders treatment provided free

Apply for This Milwaukee Location

Check if you qualify for this b-cell mediated autoimmune disorders clinical trial in Milwaukee, WI

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Milwaukee

    Convenient for WI residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Milwaukee site if eligible
  4. 4Begin participation

About This B-cell Mediated Autoimmune Disorders Study in Milwaukee

The main objective of the study is to determine the recommended phase 2 dose (RP2D) of Azercabtagene zapreleucel (azer-cel).

Sponsor: TG Therapeutics, Inc.

Who Can Participate

Inclusion Criteria

PMS and RMS inclusion criteria:
Age 18 years to ≤60 years (inclusive) at screening.
Expanded Disability Status Scale (EDSS) score 3.0 - 6.5 (inclusive) at screening.
Diagnosis of primary progressive multiple sclerosis (PPMS), secondary progressive multiple sclerosis (non-active or active), or Relapsing MS (RMS).
Documented evidence of disability progression independent of relapse (PIRA) at any point over the 12 months prior to the screening visit. NMOSD inclusion criteria:
Between age 18 and 65 years, inclusive at the time of signing the informed consent.
EDSS score between 2.0 and 7.0 at screening, inclusive (for higher EDSS, the Investigator must assess that the participant is reasonably able to participate in the study).
Diagnosis of anti-aquaporin-4 immunoglobulin G (AQP4-IgG) seropositive at screening (verified by the allocated central laboratory) and Neuromyelitis Optica Spectrum Disorder (NMOSD).
Must meet the appropriate NMOSD treatment washout criteria prior to receiving lymphodepletion. MG Inclusion criteria:
Age ≥18 and ≤70 years of age at the time of signing the informed consent.
Diagnosed with gMG at least 1 year prior to the date of signing the informed consent.
Confirmation of MG Diagnosis:
Positive serologic test for anti-acetylcholine receptor (AChR) antibodies or anti-muscle-specific kinase (MuSK) antibodies confirmed at screening AND
One of the following (either historical or during screening):
Abnormal neuromuscular transmission test demonstrated by single-fiber electromyography or repetitive nerve stimulation.
Positive anticholinesterase test (e.g., edrophonium chloride test).
Demonstrated improvement in MG signs on oral cholinesterase inhibitors, as assessed by the treating physician.
MG activities of daily living (MG-ADL) score ≥6 at screening. CIDP Inclusion criteria
Age ≥18 and ≤70 years of age at the time of signing the informed consent.
Participant must have either typical CIDP, or one of the following two CIDP variants: motor CIDP, multifocal CIDP (also known as Lewis Sumner Syndrome).
CIDP Disease Activity Status (CDAS): CDAS score ≥3 at screening.
INCAT Disability Score: INCAT disability score ≥4 to ≤9 score at screening. General

Exclusion Criteria

History of malignancy that has not been in remission for at least 2 years.
Viral Screening
Evidence of chronic active or history of hepatitis B virus (HBV).
Seropositive for human immunodeficiency virus (HIV) antibody.
History of bone marrow/hematopoietic stem cell or solid organ transplantation.
Prior treatment with adoptive T-cell therapy or any gene therapy product directed at any target (e.g. CAR T-cell therapy). Note: Other protocol-specified Inclusion/Exclusion criteria may apply.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Milwaukee?

Yes, this clinical trial (NCT06680037) has an active research site in Milwaukee, WI that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

B-cell Mediated Autoimmune Disorders Treatment Options in Milwaukee, WI

If you're searching for b-cell mediated autoimmune disorders treatment options in Milwaukee, WI, this clinical trial (NCT06680037) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Milwaukee research site is actively enrolling participants for this clinical trial. You'll receive care from experienced b-cell mediated autoimmune disorders specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all b-cell mediated autoimmune disorders clinical trials near you to find additional studies recruiting in your area.

More Multiple Myeloma Trials in Milwaukee, WI

See all multiple myeloma clinical trials recruiting in Milwaukee — not just this study.

Browse Multiple Myeloma Trials in Milwaukee →

Browse More Trials by Condition

Multiple Myeloma TrialsErectile Dysfunction TrialsOsteogenesis Imperfecta TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Milwaukee?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Milwaukee, WI